Table 1 Baseline characteristics
AssessmentPlacebo n = 785 mg/kg Infliximab n = 201
Men, no. (%)68 (87.2)157 (78.1)
Disease duration, years
    n76201
    Mean (SD)11.9 (8.0)10.1 (8.7)
    Median (IQ range)13.2 (3.7, 17.9)7.7 (3.3, 14.9)
HLA-B27 positive
    n78200
    No. (%)69 (88.5)173 (86.5)
Inflammation (average morning stiffness on a visual analogue scale 0–10 cm)
    n78201
    Mean (SD)6.9 (1.9)6.9 (2.3)
    Median (IQ range)7.0 (5.7, 8.3)7.3 (5.4, 8.5)
BASDAI score
    n78201
    Mean (SD)6.2 (1.6)6.5 (1.5)
    Median (IQ range)6.5 (5.2, 7.1)6.6 (5.3, 7.6)
C-reactive protein (mg/dl)
    n78201
    No. (%) with values ⩾LLOQ78 (100)201 (100)
    Mean (SD)2.4 (2.8)2.4 (2.7)
    Median (IQ range)1.7 (0.7, 3.3)1.5 (0.7, 3.2)
Interleukin-6 (pg/ml)
    n67187
    No. (%) with values ⩾LLOQ32 (47.8)105 (56.1)
    Mean (SD)11.4 (17.2)13.2 (20.0)
    Median (IQ range)3.1 (3.1, 14.8)7.7 (3.1, 14.2)
Vascular endothelial growth factor (pg/ml)
    n75193
    No. (%) with values ⩾LLOQ75 (100.0)191 (99.0)
    Mean (SD)556.2 (385.6)520.4 (361.5)
    Median (IQ range)473.5 (289.5, 738.0)421.5 (279.9, 664.3)
Interferon-γ (pg/ml)
    n62165
    No. (%) with values ⩾LLOQ3 (4.8)9 (5.5)
    Mean (SD)0.7 (1.3)0.6 (0.3)
    Median (IQ range)0.5 (0.5, 0.5)0.5 (0.5, 0.5)
  • BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; IQ, interquartile; LLOQ, lower limit of quantification.